These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2177347)

  • 21. Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines.
    Xiao Z; Wang C; Zhou M; Hu S; Jiang Y; Huang X; Li N; Feng J; Tang F; Chen X; Ding J; Chen L; Wang Y; Li X
    J Ethnopharmacol; 2019 Jan; 228():110-122. PubMed ID: 30243827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
    Ellis PA; Smith IE; Hardy JR; Nicolson MC; Talbot DC; Ashley SE; Priest K
    Br J Cancer; 1995 Feb; 71(2):366-70. PubMed ID: 7530988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Docetaxel (Taxotere) as first-line therapy of advanced non-small cell lung cancer (NSCLC)].
    Manegold C
    Onkologie; 2003 Dec; 26 Suppl 7():26-32. PubMed ID: 14716139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
    Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
    Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
    Song SY; Kim WS; Kim K; Jung CW; Im YH; Kim HJ; Kang WK; Lee HG; Kwon OJ; Rhee CH; Park CH; Park K
    Jpn J Clin Oncol; 2003 Oct; 33(10):509-13. PubMed ID: 14623918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced non-small-cell lung cancer.
    Komuro M; Kaneko M; Narukawa M
    Tumori; 2015; 101(4):424-32. PubMed ID: 25908047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
    Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
    J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drugs in the palliative chemotherapy of advanced non-small-cell lung cancer.
    Malayeri R; Pirker R; Huber H
    Onkologie; 2001 Oct; 24(5):416-21. PubMed ID: 11694767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
    Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
    Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
    J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.
    Souquet PJ; Chauvin F; Boissel JP; Cellerino R; Cormier Y; Ganz PA; Kaasa S; Pater JL; Quoix E; Rapp E
    Lancet; 1993 Jul; 342(8862):19-21. PubMed ID: 8100290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.
    Pujol JL; Pirker R; Lynch TJ; Butts CA; Rosell R; Shepherd FA; Vansteenkiste J; O'Byrne KJ; de Blas B; Heighway J; von Heydebreck A; Thatcher N
    Lung Cancer; 2014 Feb; 83(2):211-8. PubMed ID: 24332319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer.
    Aggarwal C; Langer CJ
    Curr Opin Oncol; 2012 Mar; 24(2):130-6. PubMed ID: 22314616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line treatment for advanced non-small-cell lung cancer.
    Laskin JJ; Sandler AB
    Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triplet chemotherapy combinations with new agents: is there a rationale?
    Bunn PA
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):55-61. PubMed ID: 9728586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.